Incyte (MEX:INCY) Other Current Payables: MXN0 Mil (As of Mar. 2026)


MEX:INCY Incyte Corp MEX:INCY
82 GF Score
Price MXN2,067.00
GF Value MXN1,812.99
Valuation Modestly Overvalued
! 4 Warning Signs
View Full Analysis

What is Incyte Other Current Payables?

Incyte MEX:INCY 82 Other Current Payables is MXN0 Mil as of Mar. 2026. GuruFocus rates MEX:INCY with a GF Score™ of 82/100 and a GF Value™ of MXN1,812.99 (Modestly Overvalued). The stock has 4 warning signs investors should review.

Incyte's Other Current Payables for the quarter that ended in Mar. 2026 was MXN0 Mil.

Incyte's quarterly Other Current Payables declined from Sep. 2025 (MXN0 Mil) to Dec. 2025 (MXN-0 Mil) but then increased from Dec. 2025 (MXN-0 Mil) to Mar. 2026 (MXN0 Mil).

Incyte's annual Other Current Payables increased from Dec. 2023 (MXN-0 Mil) to Dec. 2024 (MXN0 Mil) but then declined from Dec. 2024 (MXN0 Mil) to Dec. 2025 (MXN-0 Mil).

Incyte Other Current Payables Related Terms

Incyte Other Current Payables Historical Data

* Premium members only.

The historical data trend for Incyte's Other Current Payables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Incyte Other Current Payables Chart

Incyte Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Other Current Payables
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -0.00 -0.00 0.00 -0.00

Incyte Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Other Current Payables Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 -0.00 0.00
MEX:INCY
82GF Score
Incyte Corp MEX:INCY
Other Current Payables is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Incyte Other Current Payables Calculation

Other Current Payables is the payables owed and expected to be paid within one year or one operating cycle that not otherwise classified. It includes dividends payable and all other current payables.

Frequently Asked Questions Learn more about Other Current Payables →
What does a Other Current Payables of MXN0 Mil mean?
Incyte (MEX:INCY) has a Other Current Payables of MXN0 Mil as of Mar. 2026. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Incyte and its competitors.
Is Incyte's Other Current Payables too high?
Incyte's current Other Current Payables is MXN0 Mil. Overall, Incyte has a GF Score™ of 82/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Incyte's Other Current Payables compare to INSM and BNTX?
Incyte's Other Current Payables of MXN0 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Other Current Payables for a Biotechnology company?
A good Other Current Payables depends on the Biotechnology industry context. However, Other Current Payables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Other Current Payables mean?
A high Other Current Payables can signal that a stock is expensive relative to its fundamentals. Other Current Payables is the payables owed and expected to be paid within one year that not otherwise classified. View historical data on Incyte and its competitors. Incyte's current Other Current Payables is MXN0 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Incyte stock overvalued right now?
Based on GuruFocus' analysis, Incyte (MEX:INCY) is currently considered Modestly Overvalued. The stock's GF Value™ is MXN1,812.99, compared to a current price of MXN2,067.00 — trading 14% above its estimated fair value. The current Other Current Payables is MXN0 Mil. Incyte's overall GF Score™ is 82/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Other Current Payables calculated?
Other Current Payables is calculated from a company's financial statements. For Incyte (MEX:INCY), the current Other Current Payables is MXN0 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Incyte (MEX:INCY) Overvalued in 2026?

Based on GuruFocus' analysis, Incyte stock appears to be overvalued. The current stock price of MXN2,067.00 is trading 14% above its estimated GF Value™ of MXN1,812.99. GuruFocus considers Incyte to be Modestly Overvalued.

Key valuation signals for MEX:INCY:

  • Other Current Payables: MXN0 Mil
  • GF Value™: MXN1,812.99 vs. price of MXN2,067.00 (14% above fair value)
  • GF Score™: 82/100 with 4 warning signs

No single metric tells the full story. See the MEX:INCY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Incyte Business Description

Address 1801 Augustine Cut-Off, Wilmington, DE, USA, 19803
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
82GF Score

Get the complete analysis for MEX:INCY

Other Current Payables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

MXN2,067.00
Price
MXN1,812.99
GF Value